Drinking Coffee May Reduce Incident CVD, Mortality Risks
MONDAY, Oct. 3, 2022 (HealthDay News) -- Intake of all types of coffee is associated with reduced incident cardiovascular disease and all-cause mortality, according to a study published online Sept. 27 in the European Journal of Preventive Cardiology.
David Chieng, M.B.B.S., from the Baker Heart and Diabetes Research Institute in Melbourne, Australia, and colleagues examined the association between coffee subtypes and cardiovascular outcomes. Coffee subtypes were defined as decaffeinated, ground, and instant. Data were included for 449,563 participants who were followed over 12.5 ± 0.7 years.
The researchers observed an association for ground and instant coffee consumption with a significant reduction in arrhythmia at one to five cups/day; no association was seen for decaffeinated coffee. The lowest risks were seen for four to five cups/day of ground coffee and for two to three cups/day of instant coffee (hazard ratios, 0.83 and 0.88, respectively). All coffee subtypes were associated with a reduction in incident cardiovascular disease versus nondrinkers, with the lowest risk for two to three cups/day of decaffeinated, ground, and instant coffee. A significant reduction was seen in all-cause mortality in association with all coffee subtypes, with the greatest risk reduction for two to three cups/day of decaffeinated, ground, and instant coffee (hazard ratios, 0.86, 0.73, and 0.89, respectively).
"Mild-moderate coffee intake of all types should not be discouraged but rather considered part of a healthy lifestyle," the authors write.
Two authors disclosed financial ties to the medical device industry.
Related Posts
Gear Up (Helmets Included) for a Safe Bike Season
MONDAY, March 20, 2023 (HealthDay News) -- As the weather warms, folks are...
Some Younger Women With Early-Stage Breast Cancers Might Skip Radiation
TUESDAY, June 7, 2022 (HealthDay News) -- Tens of thousands of breast cancer...
Biden vuelve a promover la iniciativa Misión Contra el Cáncer
MARTES, 13 de septiembre de 2022 (HealthDay News) -- El lunes, el Presidente Joe...
ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events
THURSDAY, June 22, 2023 (HealthDay News) -- For men with preexisting...